Negocie BioNTech BNTX

Venda
 Comprar

Gráfico BioNTech ao vivo

5m 15m 30m 1h 4h 1d 1w

Fundamentos do instrumento

Weekly Search
Weekly
Daily
Data Fechar Mudança Alteração (%): Abertura Max Min

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Últimas notícias

Mostrar mais
Ghko B 2025 Jun 05, 16:00

Trump-Musk Relationship Collapses: Tesla Stock Drops 10%

Stocks
Ghko B 2025 Jun 05, 16:00

What are the most active stocks: RKLB, LULU, WBA, LMT, SQQQ

Stocks
Darius Anucauskas 2025 Jun 05, 16:00

Morning Note: NFP Weakness Could Pressure USD While Gold Continues to Climb

Morning Note Gold Fed Forex USD
Tommy Yap 2025 Jun 05, 16:00

Morning Note: U.S. Payroll Growth, Canada Job Market Weakens, Tesla Risks EV Credits

Morning Note Fed Forex CAD TSLA
Ghko B 2025 Jun 04, 16:00

SOFI Stock Analysis: What is the 5-year forecast for SoFi?

Stocks
Ghko B 2025 Jun 04, 16:00

VOO Performance Analysis: Is Vanguard S&P 500 ETF good to invest in?

ETFs
Ghko B 2025 Jun 04, 16:00

Intel Stock Is Trending Now: What to Know about Intel Corporation (INTC)?

Stocks
Tommy Yap 2025 Jun 04, 16:00

Morning Note: ECB Rate Cut Expected; Canada PMI in Focus; EUR/USD, USD/CAD

Morning Note Forex CAD

Info

Spread

0.7848

Spread (%)

0.7218 %

Alavancagem

1:10

Juro overnight, Compra

-0.0597 %

Juro overnight, Venda

-0.0292 %

Moeda

USD

Horários de Negociação

Mercado aberto

Sexta-feira

13:31 - 19:59

Segunda-feira

13:31-19:59

Terça-feira

13:31-19:59

Quarta-feira

13:31-19:59

Quinta-feira

13:31-19:59

Análise e estatística

Abertura

---

Fechamento anterior

---

Alta/baixa em 52 semanas

--- – ---

Capitalização de mercado

26718425088

Ações em circulação

240392992

Data dos rendimentos (Próxima)

0000-00-00

Rendim Divid

2022-06-17

Data Ex-Dividendos

2022-06-02

Taxa anual futura de dividendos

0

Rendimento anual futuro de dividendos

0

EPS

-3.62

Saiba mais sobre este instrumento

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Instrumentos relacionados

Ativo
Venda
Comprar
Alteração (%):

Negociar agora

Negociar agora

Negociar agora

Negociar agora
Instrumentos relacionados

latest_education_articles

Mostrar mais
Trustpilot